Indoco Remedies Share Price Target 2026: Expert Forecast, Growth Catalysts and Key Risks

May 8, 2026
Posted by: Neeraj Pandey
Category: News

The Indoco Remedies share price target for 2026 stands at Rs 495 as per the latest analyst forecast, implying 27 percent upside from the current market price of Rs 390. Investors tracking the Indoco Remedies share price target 2026 need to understand the full picture including growth catalysts, FY27 earnings timeline, key risks, and the bull vs bear case scenarios. This article covers every dimension of the Indoco Remedies share price target thesis updated April 2026.

Click Here to Get Free Investment Predictions on Univest

Track live Indoco Remedies price, FII or DII flows and analyst targets on the Univest Screener.

Table of Contents

Indoco Remedies Company Overview

Tap to Access Best Research on Univest

Indoco Remedies (NSE: INDOCO) is a listed company in India’s Pharma sector with a market capitalisation of Rs 3570 crore. At CMP Rs 390 against a 52 week range of Rs 320 to Rs 450, the stock currently offers meaningful upside to the analyst price forecast of Rs 495. For more share price target analysis, visit Univest Blogs.

Parameter	Value
NSE Ticker	INDOCO
Sector	Pharma
CMP April 2026	Rs 390
52 Week High	Rs 450
52 Week Low	Rs 320
Market Cap	Rs 3570 crore
Trailing P/E	20x
12M Analyst Price Forecast	Rs 495
Bull Case Target	Rs 592
Bear Case Target	Rs 296

Why Analysts Set the Indoco Remedies Share Price Target at Rs 495 for 2026

FY27 Earnings Delivery and Revenue Acceleration

FY27 is the key year where analysts expect Indoco Remedies to deliver meaningful PAT growth. This is the primary variable that bridges the gap between the current CMP of Rs 390 and the Indoco Remedies share price target 2026 of Rs 495. Analysts project 15 to 20 percent PAT growth in FY27. Track Q4 results live on the Univest Screener.

Capacity addition coming on stream in FY27

Capacity addition coming on stream in FY27 is a key growth driver that analysts highlight in supporting the Indoco Remedies share price target of Rs 495. The Pharma sector is expanding at 12 to 18 percent annually, and Indoco Remedies is well-positioned to capture a rising share. Discover top Pharma stocks on the Univest Screener.

Volume growth outpacing industry average

Volume growth outpacing industry average provides an additional lever that can help Indoco Remedies exceed analyst projections and potentially push the stock toward the bull case target of Rs 592. Compare Indoco Remedies with sector peers on the Univest Screener.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s rate cut cycle that commenced in 2026 reduces Indoco Remedies’s borrowing costs and stimulates end-market demand, supporting the Indoco Remedies share price target 2026 of Rs 495.

Union Budget 2026-27 Policy Support

Budget 2026-27 capex continuity and PLI scheme extensions create a constructive backdrop for Indoco Remedies’s Pharma business, directly supporting the Indoco Remedies share price target 2026 bull case of Rs 592.

Bull Case, Base Case and Bear Case for Indoco Remedies Share Price Target

Scenario	Target	Key Assumption
Bull Case	Rs 592	FY27 revenue growth exceeds 25 percent, margin expansion of 200 bps, sector re-rating
Base Case Forecast	Rs 495	FY27 revenue growth of 15 to 18 percent, stable margins, current P/E sustained
Bear Case	Rs 296	Revenue growth disappoints below 10 percent, margin pressure, valuation de-rating

For live tracking of Indoco Remedies analyst price targets and ratings, use the Univest Screener.

Key Risks to the Indoco Remedies Share Price Target

Earnings Miss Risk

If Indoco Remedies reports quarterly earnings below expectations, the Indoco Remedies share price target will likely face downward revision. Watch Q4 FY26 results closely on Univest Screener.

Macro and Global Headwinds

The US 26 percent reciprocal tariff announcement of April 2026 has created global macro uncertainty that adds near-term risk to the Indoco Remedies share price target 2026 timeline.

Sector-Specific Risks

Regulatory changes, input cost volatility, and competitive intensity in the Pharma space could pressure margins and delay realisation of the Indoco Remedies share price target of Rs 495.

FII Outflows

Continued FII selling in Indian equities could suppress the valuation multiples needed for Indoco Remedies to reach its analyst price forecast of Rs 495 within the 12 month horizon.

Indoco Remedies Financial Snapshot FY25 to FY27

Metric	FY25 Actual	FY26 Estimate	FY27 Estimate
Revenue (Rs Cr)	Refer NSE filing	Refer NSE filing	Refer NSE/BSE filing
EBITDA Margin	Refer NSE filing	Refer NSE filing	Expected expansion
PAT (Rs Cr)	Refer NSE filing	Refer NSE filing	15 to 20 percent growth
Market Cap	Rs 3570 crore	Higher at 52W peak	Tracks price movement
P/E Ratio	20x	Current level	Target implies re-rating
52 Week High / Low	Rs 450 / Rs 320

If you want to track Indoco Remedies financial metrics, analyst ratings and peer comparisons in real time, check the Univest Screener for live data.

Technical Outlook for Indoco Remedies Share Price

Indoco Remedies is trading at Rs 390, currently attempting to build a base above its 52 week low of Rs 320. The stock needs to reclaim its 200 day moving average to confirm a meaningful recovery trend. The Indoco Remedies share price target of Rs 495 set by analysts assumes fundamental delivery over the next 12 months rather than near-term price action. Download the Univest iOS App or Univest Android App to track Indoco Remedies live price and set alerts.

Conclusion

The Indoco Remedies share price target 2026 of Rs 495 reflects analyst conviction on FY27 earnings delivery, structural sector tailwinds, and the favourable domestic macro environment. The bull case of Rs 592 is achievable if the company executes above expectations. Investors should monitor quarterly earnings, FII ownership trends and management commentary closely. For real-time tracking and research, use the Univest Screener.

This article is for informational and educational purposes only and is not investment advice. Univest is SEBI registered (INH000013776). Please consult a SEBI registered financial advisor before making any investment decision.

Frequently Asked Questions

What is the Indoco Remedies share price target for 2026?

The Indoco Remedies share price target for 2026 is Rs 495 as per the analyst price forecast, implying 27 percent upside from the current price of Rs 390. The bull case target is Rs 592 and the bear case is Rs 296.

Is Indoco Remedies a good buy at Rs 390?

At Rs 390, Indoco Remedies trades at a trailing P/E of 20x and offers potential upside to the analyst price forecast of Rs 495. Whether it is a good buy depends on your investment horizon and risk appetite. Always consult a SEBI registered financial advisor.

What is the 52 week high and low of Indoco Remedies?

The 52 week high of Indoco Remedies is Rs 450 and the 52 week low is Rs 320. The current CMP of Rs 390 positions the stock at a meaningful discount to its peak, which is factored into the analyst Indoco Remedies share price target 2026.

What sector does Indoco Remedies belong to?

Indoco Remedies belongs to India’s Pharma sector and trades on NSE with the ticker INDOCO. Track the entire Pharma sector on the Univest Screener.

What is the bull case for Indoco Remedies share price?

The bull case for Indoco Remedies share price is Rs 592, which assumes revenue growth exceeding 25 percent in FY27, margin expansion of 200 basis points, and a positive re-rating of the Pharma sector. This scenario requires strong execution and supportive macro conditions.

What are the key risks to the Indoco Remedies share price target?

Key risks include earnings miss in upcoming quarters, continued FII selling, regulatory headwinds in the Pharma sector, raw material cost volatility, and global macro uncertainty driven by the US tariff environment. These risks could push the stock toward the bear case of Rs 296.

Recent Article

Why Is Liberty Shoes Share Price Falling: Key Reasons and Investor Analysis 2026

Why Is Shemaroo Entertainment Share Price Falling: Key Reasons and Investor Analysis 2026

Why Is Orchid Pharma Share Price Falling: Key Reasons and Investor Analysis 2026

Why Is Bajaj Holdings and Investment Share Price Falling: Key Reasons and Investor Analysis 2026

Why Is Prism Johnson Share Price Falling: Key Reasons and Investor Analysis 2026

News Share Price Target

Author: Neeraj Pandey

Neeraj Pandey is a Financial Content Writer at Univest, covering Indian equity markets with a specialisation in quarterly earnings previews and analyst consensus analysis. His published work tracks Q4 FY26 results across 10+ sectors — from IT heavyweights like Infosys and TCS to PSUs like Coal India and Balmer Lawrie, and mid-caps like Neuland Laboratories, MCX, and Whirlpool of India. His writing approach is data-first: every article anchors on NSE/BSE filings, analyst consensus estimates (revenue, PAT, EBITDA margins), 52-week price context, and YoY/QoQ comparisons — giving retail investors the same structured framework institutional desks use before an earnings event. He combines SEO-optimised structure with rigorous data sourcing, ensuring each preview ranks for investor search intent while meeting SEBI editorial standards. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Equity Research Analyst, to meet SEBI editorial standards.